Antibacterial Coatings of Poly(ethylenimine)/Poly(l-lactide)-Grafted Hyaluronic Acid Multilayers Surface-Functionalized with Bacteriophages.

The infestation of tissue after implantation is a major problem as a bacterial biofilm can form on the surface of the implants, leading to implant-associated infections (IAIs). One approach to prevent such IAI is to apply antibacterial coatings consisting of polyelectrolyte multilayers (PEM) and bacteriophages (PHAGs). PEM were constructed by alternately adsorbing oppositely charged polyelectrolytes on a substrate according to the layer-by-layer concept.

[Care-related Case Management and the experienced burden of informal caregivers: empirical study].

Care-related Case Management and the experienced burden of informal caregivers: empirical study Informal caregivers are responsible for the majority of home care in Germany. Their experience of stress is becoming more and more relevant given the tense staffing situation in outpatient professional care in rural areas. Case management as an innovative approach to caring in peripheral areas also focuses on the burden experienced by informal caregivers.

Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer.

Unlabelled: Immune checkpoint blockade (ICB) is the standard of care for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), yet efficacy remains low. The current approach for predicting the likelihood of response to ICB is a single proportional biomarker (PD-L1) expressed in immune and tumor cells (Combined Positive Score, CPS) without differentiation by cell type, potentially explaining its limited predictive value. Tertiary Lymphoid Structures (TLS) have shown a stronger association with ICB response than PD-L1.

Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.

Background: Epstein-Barr virus-specific cytotoxic T lymphocyte (EBV-CTL) is an autologous adoptive T-cell immunotherapy generated from the blood of individuals and manufactured without genetic modification. In a previous phase II trial of locally recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) patients, first-line gemcitabine and carboplatin (GC) and EBV-CTL combination demonstrated objective antitumor EBV-CTL activity and a favorable safety profile. The present study explored whether this combined first-line chemo-immunotherapy strategy would produce superior clinical efficacy and better quality of life compared with conventional chemotherapy treatment.